Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Church & Dwight Hits Gummy Soft Patch, Brand Licensing Ahead

This article was originally published in The Tan Sheet

Executive Summary

Stalled production at its Vancouver, Wash., facility and a delay in starting operations at a facility in York, Pa., constrained the firm’s supply to retailers of L’il Critters children’s and Vitafusion adult gummy vitamins during the second quarter.

You may also be interested in...



Church & Dwight Wakes Up L'il Critters Children's Gummy Vitamin Line With Melatonin

Sold online and in stores at Target, L’il Critters Melatonin Gummies are $11.99 for 60, 1.5-mg melatonin gummies for use in children who have trouble falling asleep.

Church & Dwight Going At Millennials Hard With Its Gummies

Church & Dwight is reaching out to Gen Y with a splashy Vitafusion digital campaign across social media platforms including Instagram and YouTube, as well as music streaming site Pandora, Chief Marketing Officer Britta Bomhard said Sept. 4 at the Barclays Global Consumer Staples Conference in Boston. The company is also launching new packaging claiming “clinically proven absorption.”

Vitafusion Ads Aim To Bounce Gummy Competitors' Gains From Discounts

Church & Dwight introduces Vitafusion gummy vitamin ads to counter aggressive promotional discounting by competitors in the segment. The firm's domestic sales grew 9.7% in the third quarter on product launches and as digital sales soared 70%.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel